Several psychotropic compounds are known to influence the sleep-EEG. In very rare cases sleep abnormalities like parasomnia or arousal disorders have additionally been reported during psychotropic drug treatment. We report the case of a 19-year old female patient with a depressive episode and intermittent somnambulism under treatment with reboxetine. The patient with a history of somnambulism in early childhood again suffered from episodes of somnabulism which disappeared after a dose reduction of the drug. In patients having a predisposition for developing parasomnia, a treatment with reboxetine might induce somnambulism.
References
-
1
Farina B, Della Marca G, Mennuni G, Mazza S, De Risio S, Di Giannantonio M.
The effects of reboxetine on human sleep architecture in depression: preliminary results.
J Affect Dis.
2002;
71
273-275
-
2
Ferrandiz-Santos J A, Mataix-Sanjuan A L.
Amitriptyline and somnambulism.
Ann Pharmacother.
2000;
34
1208
-
3
Kolivakis T T, Margolese H C, Beauclair L. et al .
Olanzapine-Induced Somnambulism.
Am J Psychiatry.
2001;
158
1158
-
4 Kuenzel H E, Murck H, Held K, Ziegenbein M, Steiger A. Reboxetine induces similar sleep EEG changes like SSR’s in patients with depression. Pharmacopsychiatry, in press
-
5
Ohayon M M, Guilleminault C, Priest R G.
Night terrors, sleepwalking, and confusional arousals in the general population: their frequency and relationship to other sleep and mental disorders.
J Clin Psychiatry.
1999;
60
268-276
-
6
Schenck C H, Mahowald M W.
Long-term, nightly benzodiazepine treatment of injurious parasomnias and other disorders of disrupted nocturnal sleep in 170 adults.
Am J Med.
1996;
100
333-337
-
7
Stahl S M, Mendels J, Schwartz G E.
Effects of reboxetine on anxiety, agitation, and insomnia: results of a pooled evaluation of randomized clinical trials.
J Clin Psychopharmacology.
2002;
22
388-392
-
8
van Bemmel A L, Vermeeren M T, Ruigt G. et al .
The acute effects of the noradrenaline reuptake inhibitor Org 4428 on EEG sleep in healthy volunteers.
Neuropsychobiology.
1999;
40
107-114
Dr. Thomas Pollmächer
Max Planck Institute of Psychiatry
Kraepelinstraße 10
80804 Munich
Germany
Phone: +49 89 30622 572
Fax: +49 89 30622 562
Email: topo@mpipsykl.mpg.de
